Patent ID: 6696456
Filing Date: 2004-02-24
Classification: C07C,C07D

Abstract:
A compound having a structure according to Formula (I) wherein:(A) l is from 0 to about 4; (B) E is selected from a covalent bond, â€”Oâ€”, â€”Sâ€”, â€”S(O)â€”, â€”S(O2)â€”, â€”N(R10)â€”, â€”N(COR10)â€”, â€”N(CO2R10)â€”, â€”N(CONR10R10â€²)â€”, and â€”N(SO2R10)â€”, where (i) each R10 and R10â€², when present, is independently selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, and heterocycloalkyl, or (ii) R10 and R10â€², together with the nitrogen atom to which they are bonded, join to form an optionally substituted heterocyclic ring containing from 5 to 8 ring atoms of which from 1 to 3 are heteroatoms; provided That when l=0, E is a covalent bond; and (C) (1) A is selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, and heterocycloalkyl; or (2) A, together with R10, or R10â€², join to form an optionally substituted heterocyclic ring containing from 5 to 8 ring atoms of which from 1 to 3 are heteroatoms; (D) G is selected from â€”C(R11)&boxH;C(R11â€²)â€”, where each R11 and R11â€² is independently selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl; (E) Z is selected from: (1) cycloalkyl and heterocycloalkyl; (2) â€”Lâ€”(CR12R12â€²)aâ€”R13 where: (a) a is from 0 to about 4; (b) L is selected from â€”Câ‰¡Câ€”, â€”CH&boxH;CHâ€”, â€”N&boxH;Nâ€”, â€”Oâ€”, â€”Sâ€” and â€”SO2â€”; (c) each R12 and R12â€², when present, is independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, haloalkyl, hydroxy, and alkoxy; and (d) R13 is selected from hydrogen, aryl, heteroaryl, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, heterocycloalkyl and cycloalkyl; and, if L is â€”Câ‰¡Câ€” or â€”CH&boxH;CHâ€”, then R13 may also be selected from â€”CON(R14R14â€²) where (i) R14 and R14â€² are independently selected from hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, or (ii) R14 and R14â€², together with the nitrogen atom to which they arc bonded, join to form an optionally substituted heterocyclic ring containing from 5 to 8 ring atoms of which from 1 to 3 are heteroatoms; (3) â€”NR15R15â€² where: (a) R15 and R15â€² each is independently selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, aryl, heteroaryl, cycloalkyl, heteroalkyl and â€”C(O)â€”Qâ€”(CR16R16â€²)bâ€”R17 where: (i) b is from t to about 4; (ii) Q is selected from a covalent bond and â€”N(R18)â€”; and (iii) each R16 and R16â€², when present, is independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, haloalkyl, hydroxy, and alkoxy; each R17 and R18 is independently selected from hydrogen, alkyl alkenyl, alkynyl, heteroalkyl, haloalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, or R17 and R18, together with the atoms to which they are bonded, join to form an optionally substituted heterocyclic ring containing from 5 to 8 ring atoms of which from 1 to 3 are heteroatoms; or R15 and R18, together with the nitrogen atoms to which they are bonded, join to form an optionally substituted heterocyclic ring containing from 5 to 8 ring atoms of which from 2 to 3 are heteroatoms; or (b) R15 and R15â€², together with the nitrogen atom to which they are bonded, join to form an optionally substituted heterocyclic ring containing from 5 to 8 ring atoms of which from 1 to 3 are heteroatoms; and (4) â€ƒwhere: (a) Eâ€² and Mâ€² are independently selected from â€”Câ€” and â€”Nâ€”; (b) Lâ€² is selected from â€”Sâ€”, â€”Oâ€”, â€”N(R20)â€”, â€”C(R20)&boxH;C(R20â€²)â€”, â€”N&boxH;C(R20)â€”, and â€”N&boxH;Nâ€”, where each R20 and R20â€², when present, is independently selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl; (c) c is from 0 to about 4; (d) each R19 and R19â€², when present, is independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, haloalkyl, hydroxy, and alkoxy; (e) Aâ€² is selected from a covalent bond, â€”Oâ€”, â€”SOdâ€”â€”C(O)â€”, â€”C(O)N(R21)â€”, â€”N(R21)â€”, and â€”N(R21)C(O)â€”; where d is from 0 to 2 and R21 is selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, and haloalkyl: and (f) Gâ€² is â€”(CR22R22â€²)eâ€”R23 where e is from 0 to about 4; each R22 and R22â€², when present, is independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, haloalkyl, hydroxy, alkoxy and aryloxy; and R23 is selected from hydrogen, alkyl, alkenyl, alkynyl, halogen, heteroalkyl, haloalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl; or R21 and R23, together with the atoms to which they are bonded, join to form an optionally substituted heterocyclic ring containing from 5 to 8 atoms of which 1 to 3 are heteroatoms; or R20 and R23, together with the atoms to which they arc bonded, join to form an optionally substituted heterocyclic ring containing from 5 to 8 atoms of which 1 to 3 are heteroatoms; or an optical isomer, diastereomer or enantiomer for Formula (I), or a pharmaceutically-acceptable salt, or biohydrolyzable amide, ester, or imide thereof.